Clinical trials: Metastatic Clear-cell Renal Cancer
Clear Cell Renal Cell Carcinoma, Metastatic Malignant Neoplasm in the Bone
Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advanced Kidney Cancer, The PDIGREE Study
This phase III trial compares the usual treatment (treatment with ipilimumab and nivolumab followed by nivolumab alone) to treatment with ipilimumab and nivolumab, followed by nivolumab with cabozantinib in patients with…
- Conditions
- Clear Cell Renal Cell Carcinoma, Metastatic Malignant Neoplasm in the Bone, Metastatic Malignant Neoplasm in the Lymph Nodes, Metastatic Malignant Neoplasm in the Soft Tissue
- Trial name
- NCT03793166
- Testing
- Biospecimen Collection, Bone Scan, Cabozantinib
- Where
- 859 sites in United States, Puerto Rico
- Volunteers
- 1,175 people
- Sponsor
- National Cancer Institute (NCI)
Kidney Cancer
Gemcitabine and Irinotecan in Treating Patients With Metastatic Kidney Cancer
RATIONALE: Drugs used in chemotherapy, such as gemcitabine and irinotecan, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00401128
- Testing
- gemcitabine hydrochloride, irinotecan hydrochloride
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- The Cleveland Clinic
Metastatic Clear Cell Renal Cell Carcinoma
Phase II Study of Lutetium-177 Labeled Girentuximab in Patients With Advanced Renal Cancer
To determine the efficacy of multiple doses Lutetium-177-DOTA-girentuximab in patients with advanced clear cell renal cell carcinoma using RECIST criteria.
- Trial name
- NCT02002312
- Testing
- Lu-177-DOTA-girentuximab
- Where
- Netherlands
- Volunteers
- 14 people
- Sponsor
- Radboud University Medical Center
Clear Cell Renal Carcinoma
Study to Evaluate Efficacy and Safety of Sunitinib in Renal Cell Carcinoma Progressed to 1L Immunotherapy Treatment.
The therapeutic scenario of metastatic renal cancer is undergoing a new revolution with the appearance of a novel therapeutic strategy after the antiangiogenic treatments, that is the immunotherapy, in addition to the approval of…
- Trial name
- INMUNOSUN (NCT03066427)
- Testing
- Sunitinib
- Where
- 9 sites in Spain
- Volunteers
- 23 people
- Sponsor
- Spanish Oncology Genito-Urinary Group
Solid Tumor, Clear Cell Renal Cell Carcinoma
Study of CB-839 (Telaglenastat) in Combination With Talazoparib in Patients With Solid Tumors
This is a Phase 1b/2 study to determine the recommended phase 2 dose (RP2D), safety and tolerability, pharmacokinetics (PK) and clinical activity of the glutaminase inhibitor CB-839 with the poly adenosine diphosphate ribose…
- Conditions
- Solid Tumor, Clear Cell Renal Cell Carcinoma, TNBC - Triple-Negative Breast Cancer, Colorectal Cancer
- Trial name
- NCT03875313
- Testing
- CB-839, Talazoparib
- Where
- 9 sites in United States
- Volunteers
- 33 people
- Sponsor
- Calithera Biosciences, Inc
Carcinoma, Renal Cell, Clear Cell Renal Cell Carcinoma
Axitinib in Metastatic Renal Cell Carcinoma Patients With Favorable Prognostic Factors
Aim of the FavorAx study is to evaluate preliminary efficacy and safety of Axitinib in metastatic renal cell carcinoma patients with favorable IMDC prognostic factors who had progressed on sunitinib or pazopanib in the first-line…
- Trial name
- FavorAx (NCT02700568)
- Testing
- axitinib
- Where
- 15 sites in Russia
- Volunteers
- 21 people
- Sponsor
- Kidney Cancer Research Bureau
Kidney Cancer
Sorafenib in Treating Patients With Metastatic or Unresectable Kidney Cancer
RATIONALE: Sorafenib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
- Trial name
- NCT00496756
- Testing
- Sorafenib
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- University of Nebraska
Kidney Cancer
Pazopanib Versus Temsirolimus in Poor-Risk Clear-Cell Renal Cell Carcinoma (RCC)
The goal of this clinical research study is to compare pazopanib to temsirolimus in the treatment of advanced clear-cell renal cell carcinoma. The safety of each drug will also be studied.
- Trial name
- NCT01392183
- Testing
- Pazopanib, Temsirolimus, Quality of Life Assessment
- Where
- United States
- Volunteers
- 69 people
- Sponsor
- M.D. Anderson Cancer Center
Metastatic Renal Cell Carcinoma
Biological, Pathological and Imagery Markers in the First-line Treatment of Metastatic Clear-cell Renal Cell Carcinoma
The aim of this study is to identify and/or validate biomarkers and imaging markers to predict and monitor the activity of a new class of therapeutic agents called antiangiogenics for the treatment of metastatic renal cell…
- Trial name
- PREINSUT (NCT00930345)
- Testing
- Sunitinib (SUTENT)
- Where
- France
- Volunteers
- 33 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Renal Cell Carcinoma
A Study of Atezolizumab in Combination With Bevacizumab in Untreated Locally Advanced or Metastatic Clear Cell or Non-Clear Cell Renal Cell Carcinoma
Study MO39939 is an open-label, single-arm, multicenter trial in patients with unresectable, locally-advanced or metastatic, clear or non-clear cell renal cell carcinoma (RCC) who have not received prior systemic therapy (who are…
- Trial name
- NCT03693573
- Testing
- Atezolizumab, Bevacizumab
- Sponsor
- Hoffmann-La Roche
Ewing Sarcoma, Rhabdomyosarcoma
Stereotactic Body Radiotherapy (SBRT) for Pulmonary Metastases in Ewing Sarcoma, Rhabdomyosarcoma, and Wilms Tumors
This research study is studying stereotactic body radiotherapy (SBRT) as a possible treatment for lung relapse of Ewing sarcoma, rhabdomyosarcoma, osteosarcoma, non-rhabdomyosarcoma soft tissue sarcoma, Wilms tumor or other…
- Conditions
- Ewing Sarcoma, Rhabdomyosarcoma, Wilms Tumor, Osteosarcoma
- Trial name
- NCT02581384
- Testing
- Stereotactic Body Radiotherapy (SBRT)
- Where
- 3 sites in United States
- Volunteers
- 5 people
- Sponsor
- Dana-Farber Cancer Institute
Metastatic Melanoma, Advanced Locoregional Melanoma
Phase II Trial of Combination Anti-PD-1 and Aldesleukin for Metastatic Melanoma and Renal Cell Carcinoma
Background: Aldesleukin is used to treat metastatic or advanced melanoma and renal cell carcinoma. Pembrolizumab is used to treat many cancers including melanoma.
- Conditions
- Metastatic Melanoma, Advanced Locoregional Melanoma, Metastatic Renal Cell Carcinoma, Clear Cell Histology
- Trial name
- NCT05155033
- Testing
- Pembrolizumab, Aldesleukin
- Where
- United States
- Volunteers
- 78 people
- Sponsor
- National Cancer Institute (NCI)
Neoadjuvant Therapy, Advanced Cancer
Toripalimab Combined With Axitinib as Neoadjuvant Therapy for Advanced/Metastatic Non-clear Cell Renal Cell Carcinoma
This is a single-arm phase II clinical trial to evaluate the initial efficacy and safety of toripalimab combined with axitinib as neoadjuvant therapy for advanced/metastatic non-clear cell renal cell carcinoma
- Conditions
- Neoadjuvant Therapy, Advanced Cancer, Metastatic Kidney Cancer
- Trial name
- NCT04385654
- Testing
- Toripalimab, Axitinib
- Volunteers
- 40 people
- Sponsor
- West China Hospital
Advanced Renal Cell Carcinoma
AMG 386, 20060159 Phase 2, RCC 1st Line in Combination With Sorafenib
This is a phase 2, randomized, double-blind, placebo controlled, multi-center study to estimate the improvement in progression free survival (PFS) and evaluate the safety and tolerability of AMG 386 in combination with sorafenib…
- Trial name
- NCT00467025
- Testing
- AMG 386, Sorafenib
- Volunteers
- 152 people
- Sponsor
- Amgen
Clear-cell Metastatic Renal Cell Carcinoma
Evaluation of Predictive Markers for Toxicity and Efficacy in Patients With mccRCC Treated by Anti-VEGF Therapy
The purpose of this study is to assess whether certain metabonomics and/or lipidomics features in correlation with pharmacokinetics before, during and after treatment with sunitinib or pazopanib in first line can predict toxicity…
- Trial name
- METASUN (NCT02570789)
- Testing
- patients with sunitinib or pazopanib
- Where
- Belgium
- Volunteers
- 90 people
- Sponsor
- Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Advanced Clear Cell Renal Cell Carcinoma
Avelumab, Palbociclib and Axitinib in Advanced RCC
The aim of this study is to see whether the combination of 3 drugs (axitinib, avelumab and palbociclib) is safe and effective in slowing down the growth of advanced clear cell renal cell carcinoma (ccRCC) in patients that have…
- Trial name
- APART (NCT05176288)
- Testing
- Axitinib, Palbociclib, Avelumab
- Sponsor
- Bradley A. McGregor, MD
Metastatic Renal Cell Carcinoma, Metastatic Renal Cancer
A Study of Sasanlimab, Palbociclib and Axitinib in Metastatic Renal Cell Carcinoma
The goal of this research study is to evaluate how well and safely the study drugs sasanlimab, palbociclib, and axitinib work for treatment of participants with advanced clear cell renal cell carcinoma (ccRCC) or translocation…
- Conditions
- Metastatic Renal Cell Carcinoma, Metastatic Renal Cancer, Renal Cell Carcinoma, Advanced Clear Cell Renal Cell Carcinoma
- Trial name
- SPARCC (NCT07123090)
- Testing
- Sasanlimab, Palbociclib, Axitinib
- Where
- 2 sites in United States
- Volunteers
- 25 people
- Sponsor
- Stephanie Berg
Kidney Cancer
Pilot Study of Denileukin Diftitox Plus High-Dose IL-2 for Patients With Metastatic Renal Cancer
RATIONALE: Combinations of biological substances in denileukin diftitox may be able to carry tumor-killing substances directly to kidney cancer cells. Interleukin-2 may stimulate the white blood cells to kill kidney cancer cells.
- Trial name
- NCT00278369
- Testing
- aldesleukin, denileukin diftitox
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Northwestern University
Advanced or Metastatic Clear Cell Renal Cell Carcinoma
Dual-target CD70/CAIX CAR-NK Cells for Advanced Clear Cell Renal Cell Carcinoma
Phase 1/2 study evaluates the safety, feasibility, and preliminary antitumor activity of allogeneic dual-target CD70/CAIX CAR-NK cells after fludarabine/cyclophosphamide lymphodepletion in adults with advanced or metastatic clear…
- Trial name
- DUAL-NK RCC (NCT07551349)
- Testing
- EB-701/CA9-NK, Fludarabine
- Where
- China
- Volunteers
- 36 people
- Sponsor
- Beijing Biotech
Clear Cell Renal Cell Carcinoma, Metastatic Renal Cell Carcinoma
Nivolumab in Treating Patients With High-Risk Kidney Cancer Before Surgery
This pilot phase I trial studies the side effects of nivolumab and how well it works in treating patients with high-risk kidney cancer before surgery.
- Conditions
- Clear Cell Renal Cell Carcinoma, Metastatic Renal Cell Carcinoma, Stage I Renal Cell Cancer AJCC v6 and v7, Stage II Renal Cell Cancer AJCC v7
- Trial name
- NCT02595918
- Testing
- Metastasectomy, Nephrectomy, Nivolumab
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- National Cancer Institute (NCI)